Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) Other Operating Expenses (2019 - 2025)

Tvardi Therapeutics' Other Operating Expenses history spans 5 years, with the latest figure at -$1.2 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 22.6% to -$1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.6 million, a 197.03% decrease, with the full-year FY2025 number at -$5.2 million, down 120.57% from a year prior.
  • Other Operating Expenses hit -$1.2 million in Q4 2025 for Tvardi Therapeutics, up from -$1.3 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for TVRD hit a ceiling of $3.1 million in Q3 2022 and a floor of -$2.0 million in Q2 2025.
  • Historically, Other Operating Expenses has averaged $521000.0 across 4 years, with a median of $614000.0 in 2023.
  • Biggest five-year swings in Other Operating Expenses: increased 24.46% in 2023 and later plummeted 1134.76% in 2025.
  • Tracing TVRD's Other Operating Expenses over 4 years: stood at $2.1 million in 2022, then plummeted by 71.46% to $608000.0 in 2023, then tumbled by 365.62% to -$1.6 million in 2024, then grew by 22.6% to -$1.2 million in 2025.
  • Business Quant data shows Other Operating Expenses for TVRD at -$1.2 million in Q4 2025, -$1.3 million in Q3 2025, and -$2.0 million in Q2 2025.